Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD

The management of acquired reactive perforating collagenosis (ARPC) is challenging. Here, we shared two cases of ARPC combined with elderly atopic dermatitis (AD) that did not respond well to conventional treatment but responded well to the monotherapy of dupilumab, which suggests that dupilumab may...

Descripción completa

Detalles Bibliográficos
Autores principales: Ying, Yang, Shuang, Chen, Zhen‐Ying, Zhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926492/
https://www.ncbi.nlm.nih.gov/pubmed/34953055
http://dx.doi.org/10.1002/iid3.574
_version_ 1784670248352350208
author Ying, Yang
Shuang, Chen
Zhen‐Ying, Zhang
author_facet Ying, Yang
Shuang, Chen
Zhen‐Ying, Zhang
author_sort Ying, Yang
collection PubMed
description The management of acquired reactive perforating collagenosis (ARPC) is challenging. Here, we shared two cases of ARPC combined with elderly atopic dermatitis (AD) that did not respond well to conventional treatment but responded well to the monotherapy of dupilumab, which suggests that dupilumab may be an alternative option for the treatment.
format Online
Article
Text
id pubmed-8926492
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-89264922022-03-24 Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD Ying, Yang Shuang, Chen Zhen‐Ying, Zhang Immun Inflamm Dis Commentary The management of acquired reactive perforating collagenosis (ARPC) is challenging. Here, we shared two cases of ARPC combined with elderly atopic dermatitis (AD) that did not respond well to conventional treatment but responded well to the monotherapy of dupilumab, which suggests that dupilumab may be an alternative option for the treatment. John Wiley and Sons Inc. 2021-12-24 /pmc/articles/PMC8926492/ /pubmed/34953055 http://dx.doi.org/10.1002/iid3.574 Text en © 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Ying, Yang
Shuang, Chen
Zhen‐Ying, Zhang
Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD
title Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD
title_full Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD
title_fullStr Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD
title_full_unstemmed Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD
title_short Dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with AD
title_sort dupilumab may be an alternative option in the treatment of acquired reactive perforating collagenosis combined with ad
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926492/
https://www.ncbi.nlm.nih.gov/pubmed/34953055
http://dx.doi.org/10.1002/iid3.574
work_keys_str_mv AT yingyang dupilumabmaybeanalternativeoptioninthetreatmentofacquiredreactiveperforatingcollagenosiscombinedwithad
AT shuangchen dupilumabmaybeanalternativeoptioninthetreatmentofacquiredreactiveperforatingcollagenosiscombinedwithad
AT zhenyingzhang dupilumabmaybeanalternativeoptioninthetreatmentofacquiredreactiveperforatingcollagenosiscombinedwithad

Ejemplares similares